Abstract:Fluoroquinolone resistance in Mycoplasma hominis and Ureaplasma spp. is on the rise globally, which has compromised the efficacy of the currently available antimicrobial agents. This study evaluated the antimicrobial activity of two new fluoroquinolones, delafloxacin and finafloxacin, for the first time, against M. hominis and Ureaplasma spp. clinical isolates. The in vitro activity of two new fluoroquinolones, delafloxacin and finafloxacin, were evaluated against M. hominis and Ureaplasma spp. The MICs of delafloxacin, finafloxacin, and two classical fluoroquinolones (moxifloxacin and levofloxacin) were tested against 29 M. hominis and 67 Ureaplasma spp. isolates using the broth microdilution method. The molecular mechanisms underlying fluoroquinolone resistance were also investigated. Delafloxacin exhibited low MICs against M. hominis and Ureaplasma spp., including the levofloxacin-resistant isolates. For M. hominis, delafloxacin showed low MIC90 value of 1 mu g/mL (MIC range, <0.031 -1 mu g/mL) compared to 8 mu g/mL for finafloxacin, 16 mu g/mL for moxifloxacin, and 32 mu g/mL for levofloxacin. For U. parvum and U. urealyticum, delafloxacin had low MIC90 values (U. parvum, 2 mu g/mL; U. urealyticum, 4 mu g/mL) compared to 16 -32 mu g/mL for finafloxacin, 16 mu g/mL for moxifloxacin, and 32 - >32 mu g/mL for levofloxacin. The two mutations GyrA S153L and ParC S91I were commonly identified in fluoroquinolone-resistant M. hominis, and ParC S83L was the most frequent mutation identified in fluoroquinolone-resistant Ureaplasma spp. Delafloxacin displayed lower MICs against fluoroquinolone-resistant isolates of both M. hominis and Ureaplasma spp. that have mutations in the quinolone resistance determining regions (QRDRs) than the two classical fluoroquinolones. Delafloxacin is a promising fluoroquinolone with low MICs against fluoroquinolone-resistant M. hominis and Ureaplasma spp. Our study confirms the potential clinical use of delafloxacin in treating antimicrobial-resistant M. hominis and Ureaplasma spp. infections. IMPORTANCE Fluoroquinolone resistance in Mycoplasma hominis and Ureaplasma spp. is on the rise globally, which has compromised the efficacy of the currently available antimicrobial agents. This study evaluated the antimicrobial activity of two new fluoroquinolones, delafloxacin and finafloxacin, for the first time, against M. hominis and Ureaplasma spp. clinical isolates. Delafloxacin and finafloxacin displayed different antimicrobial susceptibility profiles against M. hominis and Ureaplasma spp. in vitro. Delafloxacin was found to be more effective against M. hominis and Ureaplasma spp. than three classical fluoroquinolones (finafloxacin, moxifloxacin, and levofloxacin). Finafloxacin displayed activity similar to moxifloxacin but superior to levofloxacin against M. hominis and Ureaplasma spp. Our findings demonstrate that delafloxacin is a promising fluoroquinolone with outstanding activity against fluoroquinolone-resistant M. hominis and Ureaplasma spp.

Primary study of antofloxaicn breakpoints with disc-diffusion sensitivity test

A primary study of antofloxaicn breakpoints for agar-dilution sensitivity test

In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China

Levofloxacin susceptibility testing for Helicobacter pylori in China: comparison of E-test and disk diffusion method.

Evaluation of Cefoxitin Disk Diffusion Test for the Detection of Methicillin Resistant Staphylococcus Aureus

<i>In Vitro</i> Activity of Delafloxacin and Finafloxacin against Mycoplasma hominis and <i>Ureaplasma</i> Species

The In-Vitro Sustained Effects of Antofloxacin Hydrochloride against Staphylococcus Aureus and Escherichia Coli

Antimicrobial activities of sitafloxacin and comparators against the clinical isolates of less common nonfermenting Gram-negative bacteria

Comparative Activities of Sitafloxacin Against Recent Clinical Isolates in Hospitals Across China

Antimicrobial Resistance Surveillance of Flomoxef in China

Comparison of antibacterial activities of different concentrations of the cefoperazone-sulbactam combination disc upon commonly found gram negative bacilli

Pharmacokinetics/pharmacodynamics of Antofloxacin Hydrochloride in a Neutropenic Murine Thigh Model Ofstaphylococcus Aureusinfection

Study in Vitro of Antimicrobial Activity of Domestic Sparfloxacin

Effect of new breakpoints proposed by Clinical and Laboratory Standards Institute for evaluating antibiotics-resistance of Streptococcus pneumoniae non-meningitis strains isolated from children

A Phase Ii Study of Antofloxacin Hydrochloride, A Novel Fluoroquinolone, for the Treatment of Acute Bacterial Infections

Comparison of available methods to evaluate cefiderocol susceptibility in Acinetobacter spp

In Vivo Bioluminescent Monitoring of Therapeutic Efficacy and Pharmacodynamic Target Assessment of Antofloxacin Against Escherichia Coli in a Neutropenic Murine Thigh Infection Model.

Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, after single oral dose administration in Chinese healthy male volunteers.

Dose Findings of Antofloxacin Hydrochloride for Treating Bacterial Infections in an Early Clinical Trial Using PK-PD Parameters in Healthy Volunteers

Assessment of Lefamulin 20 Μg Disk Versus Broth Microdilution when Tested Against Common Respiratory Pathogens

Comparative in vitro activity of Delafloxacin and other antimicrobials against isolates from patients with acute bacterial skin, skin-structure infection and osteomyelitis